A drug-like imidazole-benzothiazole conjugate inhibits malignant melanoma by stabilizing the c-MYC G-quadruplex
- 20 April 2020
- journal article
- research article
- Published by Elsevier BV in Bioorganic Chemistry
- Vol. 99, 103866
- https://doi.org/10.1016/j.bioorg.2020.103866
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81803348, 21672268)
- Natural Science Foundation of Guangdong Province (2018A030310580, 2017B030314030)
- Shenzhen Science and Technology Innovation Commission (JCYJ20170818141916158, 2017B030314030)
- Guangdong Provincial Key Laboratory of Construction Foundation
This publication has 39 references indexed in Scilit:
- Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatmentInternational Immunopharmacology, 2017
- Targeted agents and immunotherapies: optimizing outcomes in melanomaNature Reviews Clinical Oncology, 2017
- Melanoma immunotherapy dominates the fieldAnnals of Translational Medicine, 2016
- Advances in immunotherapy for melanomaBMC Medicine, 2016
- Malignant melanoma: diagnosis, treatment and cancer stem cellsNeoplasma, 2016
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodiesAnnals Of Oncology, 2015
- The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K InhibitionClinical Cancer Research, 2013
- Systematic Review of Medical Treatment in Melanoma: Current Status and Future ProspectsThe Oncologist, 2011
- Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trialsThe Lancet Oncology, 2003
- c-Myc Target Genes Involved in Cell Growth, Apoptosis, and MetabolismMolecular and Cellular Biology, 1999